**CURRICULUM DELL’ATTIVITA’ SCIENTIFICA E DIDATTICA**

**(redatto ai sensi degli Artt. 46 e 47 del D.P.R. 28.12.2000, n. 445)**

Il sottoscritto **Emanuele D’Amico,** nato a Catania (Italia), il 07.09.1982

Indirizzo di Residenza: Via delle Camelie, 11, Valverde (CT), Italia.

Cittadinanza: Italiana,

consapevole, ai sensi dell’art. 76 del D.P.R. 445/2000, che dichiarazioni mendaci, formazione o uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali in materia,

**DICHIARA:**

**Informazioni Personali**

E-mail: [emanueledamico82@gmail.com](mailto:emanueledamico82@gmail.com)

Mobile: +393478640929

**Lingue**

Italiano: madrelingua

Inglese: fluente

Tedesco: scolastico

**EDUCAZIONE**

2001-2007: **Laurea in Medicina e Chirurgia.** Università degli studi di Catania- Votazione: 110/110 cum laude. Tesi: Dysphagia in Multiple Sclerosis.

2008-2013 **Specializzazione di Neurologia** presso ilPoliclinico Ospedaliero Universitario “Gaspare Rodolico”, Clinica Neurologica I, Università degli studi di Catania, sotto la direzione del Prof. Zappia.

2011-2012 Research fellow: **ALS center, Columbia University, Columbia Medical Center, New York, USA** sotto la supervisione del Prof. Hiroshi Mitsumoto, partecipando come co-investigator nei seguenti progetti di ricerca: Multicenter ALS Cohort Study of Oxidative Stress and Disease Progression, Multicenter PLS Cohort Study of Oxidative Stress and Disease Progression

Ottobre 2014-Dicembre 2014:frequenza presso ambulatorio di SM e Liquor Lab presso la **Clinica Universitaria di Ulm**, Germania, sotto la supervisione del Prof. Tumani

**ESPERIENZE LAVORATIVE**

**15 Gennaio 2018 ad oggi:** dirigente medico-ricercatore universitario a tempo determinato presso Azienda ospedaliera universitaria G. Rodolico Catania.

**Marzo 2017-15 Gennaio 2018:** incarico a tempo indeterminato di Dirigente Medico di I livello presso U.O. di Neurologia, Ospedale Padova Sud, Madre Teresa di Calcutta, ULSS 17- Regione Veneto.

**Novembre 2016-Febbraio 2017:** incarico a tempo determinato di Dirigente Medico di I livello presso U.O. di Neurologia, Ospedale Padova Sud, Madre Teresa di Calcutta, ULSS 17- Regione Veneto.

**Luglio 2015-Luglio 2016:** Medico Neurologo volontario presso Clinica Neurologica, Università degli studi di Catania, sotto la direzione del Prof. Zappia.

**Settembre 2013-Settembre 2014:** incarico a tempo determinato di Dirigente Medico di I livello presso U.O. di Neurologia presso Fondazione Istituto San Raffaele G. Giglio di Cefalù

**Aprile 2013-Luglio 2013:** Direttore Sanitario presso C.A.R./A.I.A.S. Onlussede diPalazzolo Acreide e Pachino (SR)

**Luglio 2013:** Specialista Ambulatoriale presso ASP CATANIA(sostituzione per 36 h totali).

**COMPETENZE PROFESSIONALI:**

Medico specialista neurologo con esperienze nell’accertamento, presa in carico e trattamento delle principali patologie acute e croniche del SNC e SNP. Particolarmente sviluppato nella gestione delle patologie demielinizzanti del SNC. In ambito ambulatoriale, in grado di eseguire esami ENG-EMG, refertazione esami EEG e potenziali evocati.

**ATTIVITA’ DI RICERCA**

**AWARDS**

Vincitore della IX edizione del Premio Reggio con il progetto dal titolo *Dolore neuropatico nella Sclerosi Multipla: esiste un legame con specifici siti di demielinizzazione?*

Attiva e continua ricerca nel campo della Sclerosi Multipla, SLA e malattie del motoneurone.

Membro del COSMOS Study Group-Columbia University, New York

**CLINICAL TRIALS**

L’esperienza come co-investigator nei seguenti phase II-III clinical trials ha permesso l’acquisizione di competenze nella gestione di nuovi farmaci orali ed iniettivi nel trattamento della Sclerosi Multipla: [*27820 Oral Cladribine Extension*](http://www.neurostatus.net/e-test/main.php?file=my_studies&study_id=24wwbu)*,* [*205MS301DECIDE*](http://www.neurostatus.net/e-test/main.php?file=my_studies&study_id=xr4nup)*,* [*101MS325 SURPASS*](http://www.neurostatus.net/e-test/main.php?file=my_studies&study_id=45zf39)*,* [*EFC6058-TERACLES*](http://www.neurostatus.net/e-test/main.php?file=my_studies&study_id=5gf4me)*,* [*SOLAR*](http://www.neurostatus.net/e-test/main.php?file=my_studies&study_id=7ytftm)*,* [*MS-LAQ-302*](http://www.neurostatus.net/e-test/main.php?file=my_studies&study_id=8urcc6)*,* [*205MS303 EXTEND*](http://www.neurostatus.net/e-test/main.php?file=my_studies&study_id=ranmvt)*,* [*101MS206 REFINE*](http://www.neurostatus.net/e-test/main.php?file=my_studies&study_id=zw2vk6)*,* [*WA21093 OperaII*](http://www.neurostatus.net/e-test/main.php?file=my_studies&study_id=sdd84k)*,* [*FTY720D2311,*](http://www.neurostatus.net/e-test/main.php?file=my_studies&study_id=ed2vpk)[*RPC01-201*](http://www.neurostatus.net/e-test/main.php?file=my_studies&study_id=za8m7n)*,* [*215MS201SYNERGY*](http://www.neurostatus.net/e-test/main.php?file=my_studies&study_id=nkdedu)*,* [*FTY720, D2306 INFORMS*](http://www.neurostatus.net/e-test/main.php?file=my_studies&study_id=4cvudr)*,* [*MomentumMT-1303-E04/E05*](http://www.neurostatus.net/e-test/main.php?file=my_studies&study_id=a2cqwh)[*LAQ-MS-305(Concerto)*](http://www.neurostatus.net/e-test/main.php?file=my_studies&study_id=2xzh9b)*,* [*CBAF312A2304*](http://www.neurostatus.net/e-test/main.php?file=my_studies&study_id=cnpuwa)[*EFC10891/TENERE*](http://www.neurostatus.net/e-test/main.php?file=my_studies&study_id=srapxb)[*MS-GA-301 GALA*](http://www.neurostatus.net/e-test/main.php?file=my_studies&study_id=yq5xfb)*,* [*FTY720D2306E1*](http://www.neurostatus.net/e-test/main.php?file=my_studies&study_id=bqsm62)

In possesso della certificazione internazionale come valutatore clinico dei pazienti affetti da Sclerosi Multipla mediante scala internazionale Neurostatus (level C).

**CAPITOLI IN LIBRI**

Patti F., Leone C., *D’Amico E.*

Cap.7; *Therapeutic approaches: Other Pharmacological Approaches***.** pp. 70-78in:

“Cognitive Impairment in Multiple sclerosis” edited by Maria Pia Amato; ELSEVIER 2011.

**H-INDEX: 11**

**PUBBLICAZIONI EDITE IN RIVISTE INTERNAZIONALI**

1. [Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience.](https://www.ncbi.nlm.nih.gov/pubmed/30515629) D'Amico E, Zanghì A, Sciandra M, Borriello G, Callari G, Gallo A, Salemi G, Cottone S, Buccafusca M, Valentino P, Bossio RB, Grimaldi LME, Pozzilli C, Tedeschi G, Zappia M, Patti F. J Neurol. 2019 Feb;266(2):411-416. doi: 10.1007/s00415-018-9144-9. Epub 2018 Dec 4.PMID 30515629
2. [Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience.](https://www.ncbi.nlm.nih.gov/pubmed/30471585) D'Amico E, Zanghì A, Chisari CG, Fermo SL, Toscano S, Arena S, Patti F, Zappia M. Mult Scler Relat Disord. 2019 Jan;27:324-326. doi: 10.1016/j.msard.2018.09.041. Epub 2018 Oct 3.
3. Prosperini L, Annovazzi P, Boffa L, Buscarinu MC, Gallo A, Matta M, Moiola L, Musu L, Perini P, Avolio C, Barcella V, Bianco A, Farina D, Ferraro E, Pontecorvo S, Granella F, Grimaldi LME, Laroni A, Lus G, Patti F, Pucci E, Pasca M, Sarchielli P; Italian Alemtuzumab Study Group. J Neurol. 2018 Dec;265(12):2851-2860. doi: 10.1007/s00415-018-9070-x. Epub 2018 Sep 26.PMID:30259178.
4. [Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting **Multiple Sclerosis**: an Italian real-word multicenter experience.](https://www.ncbi.nlm.nih.gov/pubmed/30210582)

D'Amico E, Zanghì A, Callari G, Borriello G, Gallo A, Graziano G, Valentino P, Buccafusca M, Cottone S, Salemi G, Ragonese P, Bossio RB, Docimo R, Grimaldi LME, Pozzilli C, Tedeschi G, Zappia M, Patti F.Ther Adv Neurol Disord. 2018 Sep 10;11:1756286418796404. doi: 10.1177/1756286418796404. eCollection 2018PMID:30210582.

1. [Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study.](https://www.ncbi.nlm.nih.gov/pubmed/29956427) D'Amico E, Patti F, Zanghì A, Chisari CG, Lo Fermo S, Zappia M.Eur J Neurol. 2018 Dec;25(12):1425-1431. doi: 10.1111/ene.13745. Epub 2018 Aug 3.PMID:29956427.
2. Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience. D'Amico E, Patti F, Zanghì A, Lo Fermo S, Chisari CG, Zappia M.Expert Rev Clin Pharmacol. 2018 May;11(5):531-536. doi: 10.1080/17512433.2018.1449643. Epub 2018 Mar 13.PMID:29521113.
3. [Identifying neuropathic pain in patients with multiple sclerosis: a cross-sectional multicenter study using highly specific criteria.](https://www.ncbi.nlm.nih.gov/pubmed/29404736)Solaro C, Cella M, Signori A, Martinelli V, Radaelli M, Centonze D, Sica F, Grasso MG, Clemenzi A, Bonavita S, Esposito S, Patti F, D'Amico E, Cruccu G, Truini A; Neuropathic Pain Special Interest Group of the Italian Neurological Society.J Neurol. 2018 Apr;265(4):828-835. doi: 10.1007/s00415-018-8758-2. Epub 2018 Feb 5.
4. [Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study.](https://www.ncbi.nlm.nih.gov/pubmed/29363396) Baroncini D, Zaffaroni M, Moiola L, Lorefice L, Fenu G, Iaffaldano P, Simone M, Fanelli F, Patti F, D'Amico E, Capobianco M, Bertolotto A, Gallo P, Margoni M, Miante S, Milani N, Amato MP, Righini I, Bellantonio P, Scandellari C, Costantino G, Scarpini E, Bergamaschi R, Mallucci G, Comi G, Ghezzi A; iMED Registry and Gruppo di Studio SM-Società Italiana di Neurologia.Mult Scler. 2018 Jan 1:1352458518754364. doi: 10.1177/1352458518754364. [Epub ahead of print]PMID:29363396.
5. [Pharmacokinetic drug evaluation of daclizumab for the treatment of relapsing-remitting multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/29363337)Patti F, Chisari CG, D'Amico E, Zappia M. Expert Opin Drug Metab Toxicol. 2018 Mar;14(3):341-352. doi: 10.1080/17425255.2018.1432594. Epub 2018 Jan 30. Review.PMID:29363337
6. [The clinical value of Coop/Wonca charts in assessment of HRQoL in a large cohort of relapsing-remitting multiple sclerosis patients: Results of a multicenter study.](https://www.ncbi.nlm.nih.gov/pubmed/29055451)Pappalardo A, Chisari CG, Montanari E, Pesci I, Borriello G, Pozzilli C, D'Amico E, Patti F.Mult Scler Relat Disord. 2017 Oct;17:154-171. doi: 10.1016/j.msard.2017.07.022. Epub 2017 Jul 28.PMID29055451
7. [Induction therapy for the management of early relapsing forms of multiple sclerosis. A critical opinion.](https://www.ncbi.nlm.nih.gov/pubmed/28826278)D'Amico E, Ziemssen T, Cottone S.Expert Opin Pharmacother. 2017 Oct;18(15):1553-1556. doi: 10.1080/14656566.2017.1367383. Epub 2017 Aug 22.PMIDN28826278
8. [To stop or not to stop disease modifying therapies in secondary progressive multiple sclerosis, that is the question.](https://www.ncbi.nlm.nih.gov/pubmed/28594298)D'Amico E, Ziemssen T, Cottone S. Expert Rev Neurother. 2017 Sep;17(9):847-849. doi: 10.1080/14737175.2017.1340831. Epub 2017 Jun 16. No abstract available PMID:28594298
9. [Can new chemical therapies improve the management of **multiple sclerosis** in children?](https://www.ncbi.nlm.nih.gov/pubmed/27901353)D'Amico E, Zanghì A, Patti F.Expert Opin Pharmacother. 2017 Jan;18(1):45-55. doi: 10.1080/14656566.2016.1267139. Epub 2016 Dec 16. Review.PMID:27901353
10. [A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives.](https://www.ncbi.nlm.nih.gov/pubmed/27763513)D'Amico E, Patti F, Zanghì A, Zappia M.Int J Mol Sci. 2016 Oct 17;17(10). pii: E1725. Review.PMID 27763513
11. [Palliative care in progressive multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/27718749)D'Amico E, Zanghì A, Patti F, Zappia M. Expert Rev Neurother. 2017 Feb;17(2):123-127. doi: 10.1080/14737175.2017.1245615. Epub 2016 Oct 20.
12. [Access to home palliative care services in Italy: the experience of the ‘SAMOT Onlus’ home care unit](https://www.researchgate.net/publication/320385203_Access_to_home_palliative_care_services_in_Italy_the_experience_of_the_%27SAMOT_Onlus%27_home_care_unit?_iepl%5BviewId%5D=Sci9Ki1g1a1nNpdAoR7gyMx5&_iepl%5BprofilePublicationItemVariant%5D=default&_iepl%5Bcontexts%5D%5B0%5D=prfpi&_iepl%5BtargetEntityId%5D=PB%3A320385203&_iepl%5BinteractionType%5D=publicationTitle). [Emanuele D'Amico](https://www.researchgate.net/profile/Emanuele_Damico6?_iepl%5BviewId%5D=Sci9Ki1g1a1nNpdAoR7gyMx5&_iepl%5BprofilePublicationItemVariant%5D=default&_iepl%5Bcontexts%5D%5B0%5D=prfpi&_iepl%5BtargetEntityId%5D=PB%3A320385203&_iepl%5BinteractionType%5D=publicationViewCoAuthorProfile), [Tania Piccione](https://www.researchgate.net/scientific-contributions/2133896720_Tania_Piccione?_iepl%5BviewId%5D=Sci9Ki1g1a1nNpdAoR7gyMx5&_iepl%5BprofilePublicationItemVariant%5D=default&_iepl%5Bcontexts%5D%5B0%5D=prfpi&_iepl%5BtargetEntityId%5D=PB%3A320385203&_iepl%5BinteractionType%5D=publicationViewCoAuthorProfile), [Antonino Biondo](https://www.researchgate.net/scientific-contributions/2133919772_Antonino_Biondo?_iepl%5BviewId%5D=Sci9Ki1g1a1nNpdAoR7gyMx5&_iepl%5BprofilePublicationItemVariant%5D=default&_iepl%5Bcontexts%5D%5B0%5D=prfpi&_iepl%5BtargetEntityId%5D=PB%3A320385203&_iepl%5BinteractionType%5D=publicationViewCoAuthorProfile), [G. Trizzino](https://www.researchgate.net/scientific-contributions/2133914155_G_Trizzino?_iepl%5BviewId%5D=Sci9Ki1g1a1nNpdAoR7gyMx5&_iepl%5BprofilePublicationItemVariant%5D=default&_iepl%5Bcontexts%5D%5B0%5D=prfpi&_iepl%5BtargetEntityId%5D=PB%3A320385203&_iepl%5BinteractionType%5D=publicationViewCoAuthorProfile). Oct 2017. Expert Review of Quality of Life in Cancer Care.
13. [Depressive Symptoms Correlate with Disability and Disease Course in **Multiple Sclerosis** Patients: An Italian Multi-Center Study Using the Beck Depression Inventory.](https://www.ncbi.nlm.nih.gov/pubmed/27632167)Solaro C, Trabucco E, Signori A, Martinelli V, Radaelli M, Centonze D, Rossi S, Grasso MG, Clemenzi A, Bonavita S, D'Ambrosio A, Patti F, D'Amico E, Cruccu G, Truini A.PLoS One. 2016 Sep 15;11(9):e0160261. doi: 10.1371/journal.pone.0160261. eCollection 2016.PMID:27632167
14. [Risk factors in **multiple sclerosis**: a population-based case-control study in Sicily. Background and methods.](https://www.ncbi.nlm.nih.gov/pubmed/27488302) Nicoletti A, Messina S, Bruno E, Mostile G, Quattrocchi G, Raciti L, Dibilio V, Cappellani R, D'Amico E, Sciacca G, Lo Fermo S, Paradisi V, Patti F, Zappia M. Neurol Sci. 2016 Dec;37(12):1931-1937. Epub 2016 Aug 3 PMID27488302
15. [The Use of Immunosuppressant Therapy for **Multiple Sclerosis** in Italy: A Multicenter Retroprospective Study.](https://www.ncbi.nlm.nih.gov/pubmed/27348606)D'Amico E, Leone C, Graziano G, Amato MP, Bergamaschi R, Cavalla P, Coniglio G, Di Battista G, Ferrò MT, Granella F, Granieri E, Lugaresi A, Lus G,Millefiorini E, Pozzilli C, Tedeschi G, Zappia M, Comi G, Trojano M, Lepore V, Patti F. PLoS One. 2016 Jun 27;11(6):e0157721. doi: 10.1371/journal.pone.0157721. eCollection 2016.PMID:27348606.
16. [Lateral and escalation therapy in relapsing-remitting **multiple sclerosis**: a comparative study.](https://www.ncbi.nlm.nih.gov/pubmed/27314964)D'Amico E, Leone C, Zanghì A, Fermo SL, Patti F.J Neurol. 2016 Sep;263(9):1802-9. doi: 10.1007/s00415-016-8207-z. Epub 2016 Jun 17PMID:27314964.
17. [Disability may influence patient willingness to participate in decision making on first-line therapy in **multiple sclerosis**.](https://www.ncbi.nlm.nih.gov/pubmed/27027890)D'Amico E, Leone C, Patti F. Funct Neurol. 2016 Jan-Mar;31(1):21-3.PMID27027890.
18. [Can we define a rehabilitation strategy for cognitive impairment in progressive **multiple sclerosis**? A critical appraisal.](https://www.ncbi.nlm.nih.gov/pubmed/26920381)D'Amico E, Leone C, Hayrettin T, Patti F. Mult Scler. 2016 Apr;22(5):581-9. doi: 10.1177/1352458516632066. Epub 2016 Feb 26. Review.PMID:26920381
19. [Offspring Number Does Not Influence Reaching the Disability's Milestones in **Multiple Sclerosis**: A Seven-Year Follow-Up Study.](https://www.ncbi.nlm.nih.gov/pubmed/26907250) D'Amico E, Leone C, Patti F.Int J Mol Sci. 2016 Feb 12;17(2):234. doi: 10.3390/ijms17020234.PMID:26907250
20. [Negative prognostic impact of MRI spinal lesions in the early stages of relapsing-remitting **multiple sclerosis**.](https://www.ncbi.nlm.nih.gov/pubmed/28607716)D'Amico E, Patti F, Leone C, Lo Fermo S, Zappia M.Mult Scler J Exp Transl Clin. 2016 Feb 9;2:2055217316631565. doi: 10.1177/2055217316631565. eCollection 2016 Jan-Dec.PMID:28607716.
21. [Could autologous hematopoietic stem cell transplantation be considered a second-line treatment option in relapsing-remitting multiple sclerosis? A critical editorial](https://www.researchgate.net/publication/315935313_Could_autologous_hematopoietic_stem_cell_transplantation_be_considered_a_second-line_treatment_option_in_relapsing-remitting_multiple_sclerosis_A_critical_editorial?_iepl%5BviewId%5D=Sci9Ki1g1a1nNpdAoR7gyMx5&_iepl%5BprofilePublicationItemVariant%5D=default&_iepl%5Bcontexts%5D%5B0%5D=prfpi&_iepl%5BtargetEntityId%5D=PB%3A315935313&_iepl%5BinteractionType%5D=publicationTitle). [Emanuele D'Amico](https://www.researchgate.net/profile/Emanuele_Damico6?_iepl%5BviewId%5D=Sci9Ki1g1a1nNpdAoR7gyMx5&_iepl%5BprofilePublicationItemVariant%5D=default&_iepl%5Bcontexts%5D%5B0%5D=prfpi&_iepl%5BtargetEntityId%5D=PB%3A315935313&_iepl%5BinteractionType%5D=publicationViewCoAuthorProfile), [Salvatore Cottone](https://www.researchgate.net/scientific-contributions/2125941531_Salvatore_Cottone?_iepl%5BviewId%5D=Sci9Ki1g1a1nNpdAoR7gyMx5&_iepl%5BprofilePublicationItemVariant%5D=default&_iepl%5Bcontexts%5D%5B0%5D=prfpi&_iepl%5BtargetEntityId%5D=PB%3A315935313&_iepl%5BinteractionType%5D=publicationViewCoAuthorProfile). Apr 2017. Expert Review of Precision Medicine and Drug Development.

1. [Cognitive-motor dual-task interference: A systematic review of neural correlates.](https://www.ncbi.nlm.nih.gov/pubmed/28104413) Leone C, Feys P, Moumdjian L, D'Amico E, Zappia M, Patti F. Neurosci Biobehav Rev. 2017 Jan 16;75:348-360. doi: 10.1016/j.neubiorev.2017.01.010.
2. [Inpatient versus outpatient rehabilitation for multiple sclerosis patients: effects on disability and quality of life](https://www.researchgate.net/publication/299501454_Inpatient_versus_outpatient_rehabilitation_for_multiple_sclerosis_patients_effects_on_disability_and_quality_of_life?_iepl%5BviewId%5D=Sci9Ki1g1a1nNpdAoR7gyMx5&_iepl%5BprofilePublicationItemVariant%5D=default&_iepl%5Bcontexts%5D%5B0%5D=prfpi&_iepl%5BtargetEntityId%5D=PB%3A299501454&_iepl%5BinteractionType%5D=publicationTitle). [Angelo Pappalardo](https://www.researchgate.net/profile/Angelo_Pappalardo?_iepl%5BviewId%5D=Sci9Ki1g1a1nNpdAoR7gyMx5&_iepl%5BprofilePublicationItemVariant%5D=default&_iepl%5Bcontexts%5D%5B0%5D=prfpi&_iepl%5BtargetEntityId%5D=PB%3A299501454&_iepl%5BinteractionType%5D=publicationViewCoAuthorProfile), [Emanuele D'Amico](https://www.researchgate.net/profile/Emanuele_Damico6?_iepl%5BviewId%5D=Sci9Ki1g1a1nNpdAoR7gyMx5&_iepl%5BprofilePublicationItemVariant%5D=default&_iepl%5Bcontexts%5D%5B0%5D=prfpi&_iepl%5BtargetEntityId%5D=PB%3A299501454&_iepl%5BinteractionType%5D=publicationViewCoAuthorProfile), Carmela Leone, [Francesco Patt](https://www.researchgate.net/profile/Francesco_Patti?_iepl%5BviewId%5D=Sci9Ki1g1a1nNpdAoR7gyMx5&_iepl%5BprofilePublicationItemVariant%5D=default&_iepl%5Bcontexts%5D%5B0%5D=prfpi&_iepl%5BtargetEntityId%5D=PB%3A299501454&_iepl%5BinteractionType%5D=publicationViewCoAuthorProfile)i. Dec 2016. Pappalardo et al. Multiple Sclerosis and Demyelinating Disorders.
3. [Association Between Dietary Intake and Function in Amyotrophic Lateral Sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/27775751) Nieves JW, Gennings C, Factor-Litvak P, Hupf J, Singleton J, Sharf V, Oskarsson B, Fernandes Filho JA, Sorenson EJ, *D'Amico E,* Goetz R, Mitsumoto H; Amyotrophic Lateral Sclerosis Multicenter Cohort Study of Oxidative Stress (ALS COSMOS) Study Group. JAMA Neurol. 2016 Dec 1;73(12):1425-1432. doi: 10.1001/jamaneurol.2016.3401.
4. [Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs.](https://www.ncbi.nlm.nih.gov/pubmed/27696299) *D'Amico E,* Zanghì A, Leone C, Tumani H, Patti F. Drug Saf. 2016 Dec;39(12):1163-1174. Review.
5. [Personalized therapy in Multiple Sclerosis: state of art and future perspectives](https://www.researchgate.net/publication/303898466_Personalized_therapy_in_Multiple_Sclerosis_state_of_art_and_future_perspectives?_iepl%5BviewId%5D=WuvsuoYFSb7NnjsSz8wmPrQD&_iepl%5BprofilePublicationItemVariant%5D=default&_iepl%5Bcontexts%5D%5B0%5D=prfpi&_iepl%5BtargetEntityId%5D=PB%3A303898466&_iepl%5BinteractionType%5D=publicationTitle). Jun 2016. [Emanuele D'Amico](https://www.researchgate.net/profile/Emanuele_Damico6?_iepl%5BviewId%5D=WuvsuoYFSb7NnjsSz8wmPrQD&_iepl%5BprofilePublicationItemVariant%5D=default&_iepl%5Bcontexts%5D%5B0%5D=prfpi&_iepl%5BtargetEntityId%5D=PB%3A303898466&_iepl%5BinteractionType%5D=publicationViewCoAuthorProfile), [Aurora Zanghì](https://www.researchgate.net/profile/Aurora_Zanghi?_iepl%5BviewId%5D=WuvsuoYFSb7NnjsSz8wmPrQD&_iepl%5BprofilePublicationItemVariant%5D=default&_iepl%5Bcontexts%5D%5B0%5D=prfpi&_iepl%5BtargetEntityId%5D=PB%3A303898466&_iepl%5BinteractionType%5D=publicationViewCoAuthorProfile), [Francesco Patti](https://www.researchgate.net/profile/Francesco_Patti?_iepl%5BviewId%5D=WuvsuoYFSb7NnjsSz8wmPrQD&_iepl%5BprofilePublicationItemVariant%5D=default&_iepl%5Bcontexts%5D%5B0%5D=prfpi&_iepl%5BtargetEntityId%5D=PB%3A303898466&_iepl%5BinteractionType%5D=publicationViewCoAuthorProfile)
6. [Neurorehabilitation in Persons with Multiple Sclerosis: Scientific Basis and Options of Treatment](https://www.researchgate.net/publication/312260125_Neurorehabilitation_in_Persons_with_Multiple_Sclerosis_Scientific_Basis_and_Options_of_Treatment?_iepl%5BviewId%5D=WuvsuoYFSb7NnjsSz8wmPrQD&_iepl%5BprofilePublicationItemVariant%5D=default&_iepl%5Bcontexts%5D%5B0%5D=prfpi&_iepl%5BtargetEntityId%5D=PB%3A312260125&_iepl%5BinteractionType%5D=publicationTitle). [Angelo Pappalardo](https://www.researchgate.net/profile/Angelo_Pappalardo?_iepl%5BviewId%5D=WuvsuoYFSb7NnjsSz8wmPrQD&_iepl%5BprofilePublicationItemVariant%5D=default&_iepl%5Bcontexts%5D%5B0%5D=prfpi&_iepl%5BtargetEntityId%5D=PB%3A312260125&_iepl%5BinteractionType%5D=publicationViewCoAuthorProfile), [Emanuele D'Amico](https://www.researchgate.net/profile/Emanuele_Damico6?_iepl%5BviewId%5D=WuvsuoYFSb7NnjsSz8wmPrQD&_iepl%5BprofilePublicationItemVariant%5D=default&_iepl%5Bcontexts%5D%5B0%5D=prfpi&_iepl%5BtargetEntityId%5D=PB%3A312260125&_iepl%5BinteractionType%5D=publicationViewCoAuthorProfile), [Clara Grazia Chisari](https://www.researchgate.net/scientific-contributions/2088044611_Clara_Grazia_Chisari?_iepl%5BviewId%5D=WuvsuoYFSb7NnjsSz8wmPrQD&_iepl%5BprofilePublicationItemVariant%5D=default&_iepl%5Bcontexts%5D%5B0%5D=prfpi&_iepl%5BtargetEntityId%5D=PB%3A312260125&_iepl%5BinteractionType%5D=publicationViewCoAuthorProfile). Jan 2016. J Mult Scler.
7. [Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal.](https://www.ncbi.nlm.nih.gov/pubmed/26098146) D'Amico E, Leone C, Caserta C, Patti F. Expert Rev Neurother. 2015;15(7):803-24. doi: 10.1586/14737175.2015.1058162. Review.

1. [Do people with multiple sclerosis claim an 'active' role in the decision making process at start of first level therapy?](https://www.researchgate.net/publication/295808918_Do_people_with_multiple_sclerosis_claim_an_%27active%27_role_in_the_decision_making_process_at_start_of_first_level_therapy?_iepl%5BviewId%5D=WuvsuoYFSb7NnjsSz8wmPrQD&_iepl%5BprofilePublicationItemVariant%5D=default&_iepl%5Bcontexts%5D%5B0%5D=prfpi&_iepl%5BtargetEntityId%5D=PB%3A295808918&_iepl%5BinteractionType%5D=publicationTitle) [Carmela Leone](https://www.researchgate.net/profile/Carmela_Leone?_iepl%5BviewId%5D=WuvsuoYFSb7NnjsSz8wmPrQD&_iepl%5BprofilePublicationItemVariant%5D=default&_iepl%5Bcontexts%5D%5B0%5D=prfpi&_iepl%5BtargetEntityId%5D=PB%3A295808918&_iepl%5BinteractionType%5D=publicationViewCoAuthorProfile), [Emanuele D'Amico](https://www.researchgate.net/profile/Emanuele_Damico6?_iepl%5BviewId%5D=WuvsuoYFSb7NnjsSz8wmPrQD&_iepl%5BprofilePublicationItemVariant%5D=default&_iepl%5Bcontexts%5D%5B0%5D=prfpi&_iepl%5BtargetEntityId%5D=PB%3A295808918&_iepl%5BinteractionType%5D=publicationViewCoAuthorProfile), [Francesco Patti](https://www.researchgate.net/profile/Francesco_Patti?_iepl%5BviewId%5D=WuvsuoYFSb7NnjsSz8wmPrQD&_iepl%5BprofilePublicationItemVariant%5D=default&_iepl%5Bcontexts%5D%5B0%5D=prfpi&_iepl%5BtargetEntityId%5D=PB%3A295808918&_iepl%5BinteractionType%5D=publicationViewCoAuthorProfile) Apr 2015 20th Annual Conference on Rehabilitation in Multiple Sclerosis (RIMS).
2. A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis. [D'Amico E](http://www.ncbi.nlm.nih.gov/pubmed/?term=D%27Amico%20E%5BAuthor%5D&cauthor=true&cauthor_uid=25826609), [Messina S](http://www.ncbi.nlm.nih.gov/pubmed/?term=Messina%20S%5BAuthor%5D&cauthor=true&cauthor_uid=25826609), [Caserta C](http://www.ncbi.nlm.nih.gov/pubmed/?term=Caserta%20C%5BAuthor%5D&cauthor=true&cauthor_uid=25826609), [Patti F](http://www.ncbi.nlm.nih.gov/pubmed/?term=Patti%20F%5BAuthor%5D&cauthor=true&cauthor_uid=25826609).[Expert Opin Drug Saf.](http://www.ncbi.nlm.nih.gov/pubmed/25826609) 2015 Mar 31:1-12.
3. Monoclonal antibody therapy in multiple sclerosis: critical appraisal and new perspectives. [D'Amico E](http://www.ncbi.nlm.nih.gov/pubmed/?term=D%27Amico%20E%5BAuthor%5D&cauthor=true&cauthor_uid=25708308), [Caserta C](http://www.ncbi.nlm.nih.gov/pubmed/?term=Caserta%20C%5BAuthor%5D&cauthor=true&cauthor_uid=25708308), [Patti F](http://www.ncbi.nlm.nih.gov/pubmed/?term=Patti%20F%5BAuthor%5D&cauthor=true&cauthor_uid=25708308). [Expert Rev Neurother.](http://www.ncbi.nlm.nih.gov/pubmed/25708308) 2015 Mar;15(3):251-68. Doi 10.1586/14737175.2015.1008458.
4. Pregnancy outcomes in multiple sclerosis patients previously treated with cyclophosphamide. Patti F, Messina S, *D'Amico E*, Lo Fermo S, Zappia M. Acta Neurol Scand. 2014 Oct;130(4):e41-4. doi: 10.1111/ane.12255.
5. [Cognitive impairment and “invisible symptoms” are not associated with CCSVI in MS](https://www.researchgate.net/publication/253332200_Cognitive_impairment_and_invisible_symptoms_are_not_associated_with_CCSVI_in_MS?_iepl%5BviewId%5D=WuvsuoYFSb7NnjsSz8wmPrQD&_iepl%5BprofilePublicationItemVariant%5D=default&_iepl%5Bcontexts%5D%5B0%5D=prfpi&_iepl%5BtargetEntityId%5D=PB%3A253332200&_iepl%5BinteractionType%5D=publicationTitle). [Carmela Leone](https://www.researchgate.net/profile/Carmela_Leone?_iepl%5BviewId%5D=WuvsuoYFSb7NnjsSz8wmPrQD&_iepl%5BprofilePublicationItemVariant%5D=default&_iepl%5Bcontexts%5D%5B0%5D=prfpi&_iepl%5BtargetEntityId%5D=PB%3A253332200&_iepl%5BinteractionType%5D=publicationViewCoAuthorProfile). [Emanuele D'Amico](https://www.researchgate.net/profile/Emanuele_Damico6?_iepl%5BviewId%5D=WuvsuoYFSb7NnjsSz8wmPrQD&_iepl%5BprofilePublicationItemVariant%5D=default&_iepl%5Bcontexts%5D%5B0%5D=prfpi&_iepl%5BtargetEntityId%5D=PB%3A253332200&_iepl%5BinteractionType%5D=publicationViewCoAuthorProfile). [Sabina Cilia](https://www.researchgate.net/profile/Sabina_Cilia?_iepl%5BviewId%5D=WuvsuoYFSb7NnjsSz8wmPrQD&_iepl%5BprofilePublicationItemVariant%5D=default&_iepl%5Bcontexts%5D%5B0%5D=prfpi&_iepl%5BtargetEntityId%5D=PB%3A253332200&_iepl%5BinteractionType%5D=publicationViewCoAuthorProfile). [Francesco Patti](https://www.researchgate.net/profile/Francesco_Patti?_iepl%5BviewId%5D=WuvsuoYFSb7NnjsSz8wmPrQD&_iepl%5BprofilePublicationItemVariant%5D=default&_iepl%5Bcontexts%5D%5B0%5D=prfpi&_iepl%5BtargetEntityId%5D=PB%3A253332200&_iepl%5BinteractionType%5D=publicationViewCoAuthorProfile). July 2013. BMC Neurology.
6. [Familial clustering in Italian progressive-onset and bout-onset multiple sclerosis.](http://www.ncbi.nlm.nih.gov/pubmed/24514917) Guaschino C, Esposito F, Liberatore G, Colombo B, Annovazzi P, *D'Amico E,* Cavalla P, Capello E, Capra R, Galimberti D, Tedeschi G, Grimaldi L; PROGRESSO Group; PROGEMUS Group, Leone M, D'Alfonso S, Martinelli V, Comi G, Martinelli-Boneschi F. Neurol Sci. 2014 Feb 11. [Epub ahead of print]
7. [Genetic burden of common variants in progressive and bout-onset multiple sclerosis.](http://www.ncbi.nlm.nih.gov/pubmed/24277324) Sorosina M, Brambilla P, Clarelli F, Barizzone N, Lupoli S, Guaschino C, Osiceanu AM, Moiola L, Ghezzi A, Coniglio G, Patti F, Mancardi G, Manunta P, Glorioso N, Guerini FR, Bergamaschi R, Perla F; PROGRESSO; PROGEMUS(….,*D'Amico E)*, Martinelli V, Cusi D, Leone M, Comi G, D'Alfonso S, Martinelli-Boneschi F. Mult Scler. 2013 Nov 28.
8. [Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis.](http://www.ncbi.nlm.nih.gov/pubmed/23797033) *D'Amico E,* Factor-Litvak P, Santella RM, Mitsumoto H. Free Radic Biol Med. 2013 Dec; 65:509-27.
9. [Prevalence of patient-reported dysphagia in multiple sclerosis patients: an Italian multicenter study (using the DYMUS questionnaire).](http://www.ncbi.nlm.nih.gov/pubmed/23747002) Solaro C, Rezzani C, Trabucco E, Amato MP, Zipoli V, Portaccio E, Giannini M, Patti F, *D'Amico E,* Frau J, Lorefice L, Bonavita S, Della Corte M, Grasso MG, Finamore L, Ghezzi A, Annovazzi P, Rottoli M, Gasperini C, Restivo D, Maimone D, Rossi P, Stromillo ML, Bergamaschi R. J Neurol Sci. 2013 Aug 15;331(1-2):94-7.
10. Clinical evolution of pure upper motor neuron disease/dysfunction (PUMMD). [D'Amico E](http://www.ncbi.nlm.nih.gov/pubmed?term=D'amico%20E%5BAuthor%5D&cauthor=true&cauthor_uid=23169452)*,* [Pasmantier M](http://www.ncbi.nlm.nih.gov/pubmed?term=Pasmantier%20M%5BAuthor%5D&cauthor=true&cauthor_uid=23169452), [Lee YW](http://www.ncbi.nlm.nih.gov/pubmed?term=Lee%20YW%5BAuthor%5D&cauthor=true&cauthor_uid=23169452), [Weimer L](http://www.ncbi.nlm.nih.gov/pubmed?term=Weimer%20L%5BAuthor%5D&cauthor=true&cauthor_uid=23169452), [Mitsumoto H](http://www.ncbi.nlm.nih.gov/pubmed?term=Mitsumoto%20H%5BAuthor%5D&cauthor=true&cauthor_uid=23169452). [Muscle Nerve.](http://www.ncbi.nlm.nih.gov/pubmed/23169452##) 2012 Aug 10.
11. [Multiple sclerosis and CCSVI: a population-based case control study.](http://www.ncbi.nlm.nih.gov/pubmed/22870210) Patti F, Nicoletti A, Leone C, Messina S, *D'Amico E,* Lo Fermo S, Paradisi V, Bruno E, Quattrocchi G, Veroux P, Di Pino L, Costanzo L, Zappia M. PLoS One. 2012;7(8):e41227.

1. [Prevalence of pain in Multiple Sclerosis: A multicenter Italian study](https://www.researchgate.net/publication/278278497_Prevalence_of_pain_in_Multiple_Sclerosis_A_multicenter_Italian_study?_iepl%5BviewId%5D=WuvsuoYFSb7NnjsSz8wmPrQD&_iepl%5BprofilePublicationItemVariant%5D=default&_iepl%5Bcontexts%5D%5B0%5D=prfpi&_iepl%5BtargetEntityId%5D=PB%3A278278497&_iepl%5BinteractionType%5D=publicationTitle). [Claudio Solaro](https://www.researchgate.net/profile/Claudio_Solaro?_iepl%5BviewId%5D=WuvsuoYFSb7NnjsSz8wmPrQD&_iepl%5BprofilePublicationItemVariant%5D=default&_iepl%5Bcontexts%5D%5B0%5D=prfpi&_iepl%5BtargetEntityId%5D=PB%3A278278497&_iepl%5BinteractionType%5D=publicationViewCoAuthorProfile), [M. Cella](https://www.researchgate.net/scientific-contributions/2004173822_M_Cella?_iepl%5BviewId%5D=WuvsuoYFSb7NnjsSz8wmPrQD&_iepl%5BprofilePublicationItemVariant%5D=default&_iepl%5Bcontexts%5D%5B0%5D=prfpi&_iepl%5BtargetEntityId%5D=PB%3A278278497&_iepl%5BinteractionType%5D=publicationViewCoAuthorProfile), [E. Pedemonte](https://www.researchgate.net/scientific-contributions/2004180398_E_Pedemonte?_iepl%5BviewId%5D=WuvsuoYFSb7NnjsSz8wmPrQD&_iepl%5BprofilePublicationItemVariant%5D=default&_iepl%5Bcontexts%5D%5B0%5D=prfpi&_iepl%5BtargetEntityId%5D=PB%3A278278497&_iepl%5BinteractionType%5D=publicationViewCoAuthorProfile), [A Truini](https://www.researchgate.net/scientific-contributions/38657532_A_Truini?_iepl%5BviewId%5D=WuvsuoYFSb7NnjsSz8wmPrQD&_iepl%5BprofilePublicationItemVariant%5D=default&_iepl%5Bcontexts%5D%5B0%5D=prfpi&_iepl%5BtargetEntityId%5D=PB%3A278278497&_iepl%5BinteractionType%5D=publicationViewCoAuthorProfile) […] E. D’Amico. May 2012.17th. Annual Conference on Rehabilitation in Multiple Sclerosis (RIMS).
2. Frequency and severity of headache is worsened by Interferon-beta therapy in patients with multiple sclerosis. Patti F, Nicoletti A, Pappalardo A, Castiglione A, Lo Fermo S, Messina S, *D'Amico E,* Cimino V, Zappia M. Acta Neurol Scand: 2011 Jun 8.

1. [Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial.](http://www.ncbi.nlm.nih.gov/pubmed/20702794) Chiò A, Borghero G, Calvo A, Capasso M, Caponnetto C, Corbo M, Giannini F, Logroscino G, Mandrioli J, Marcello N, Mazzini L, Moglia C, Monsurrò MR, Mora G, Patti F, Perini M, Pietrini V, Pisano F, Pupillo E, Sabatelli M, Salvi F, Silani V, Simone IL, Sorarù G, Tola MR, Volanti P, Beghi E; LITALS Study Group (…*D’Amico E.*). Neurology. 2010 Aug 17;75(7):619-25. doi: 10.1212/WNL.0b013e3181ed9e7c. Epub 2010 Aug 11.
2. Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study. Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Picconi O, Cilia S, Cottone S, Centonze D, Gasperini C; COGIMUS Study Group (…*D’Amico E.*). Mult Scler. 2011 Aug;17(8):991-1001. doi: 10.1177/1352458511401943.
3. [Validation of the DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis.](http://www.ncbi.nlm.nih.gov/pubmed/20018144) Bergamaschi R, Rezzani C, Minguzzi S, Amato MP, Patti F, Marrosu MG, Bonavita S, Grasso MG, Ghezzi A, Rottoli M, Gasperini C, Restivo D, Maimone D, Rossi P, Stromillo ML, Montomoli C, Solaro C; DYMUS Group. Funct Neurol. 2009 Jul-Sep;24(3):159-62. Erratum in: Funct Neurol. 2010 Jul-Sep;25(3):124. D'Amico, Elio [corrected to *D'Amico, Emanuele*].
4. [Treatment options of cognitive impairment in multiple sclerosis.](http://www.ncbi.nlm.nih.gov/pubmed/20953811) Patti F, Leone C, *D'Amico E.* Neurol Sci. 2010 Nov;31(Suppl 2):S265-9. doi: 10.1007/s10072-010-0438-7. Review
5. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, Tortorella C, Simone IL, Patti F, Ghezzi A, Zipoli V, Rossi P, Pozzilli C, Salemi G, Lugaresi A, Bergamaschi R, Millefiorini E, Clerico M, Lus G, Vianello M, Avolio C, Cavalla P, Lepore V, Livrea P, Comi G, Amato MP; Italian Multiple Sclerosis Database Network (MSDN) Group. Ann Neurol. 2009 Oct;66(4):513-20.

1. [Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience.](http://www.ncbi.nlm.nih.gov/pubmed/19387545) Ghezzi A, Amato MP, Annovazzi P, Capobianco M, Gallo P, La Mantia L, Marrosu MG, Martinelli V, Milani N, Moiola L, Patti F, Pozzilli C, Trojano M, Zaffaroni M, Comi G; ITEMS (Immunomodulatory Treatment of Early-onset MS) Group. Neurol Sci. 2009 Jun;30(3):193-9. doi: 10.1007/s10072-009-0083-1. Epub 2009 Apr 22.
2. [The DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis.](http://www.ncbi.nlm.nih.gov/pubmed/18280504) Bergamaschi R, Crivelli P, Rezzani C, Patti F, Solaro C, Rossi P, Restivo D, Maimone D, Romani A, Bastianello S, Tavazzi E, D'Amico E, Montomoli C, Cosi V. J Neurol Sci. 2008 Jun 15;269(1-2):49-53. doi: 10.1016/j.jns.2007.12.021. Epub 2008 Feb 15.
3. Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica. C Tortorella,M Ruggieri,E Di Monte, […],E.D’Amico, M Trojano. J Neurol Neurosurg Psychiatry 2011;82:1355e1359. doi:10.1136/jnnp.2011.241836.

**PARTECIPAZIONE A CONGRESSI**

Costante partecipazione come relatore e uditore ai maggiori congressi internazionali nel settore della ricerca della Sclerosi Multipla (ECTRIMS; ACTRIMS) e SLA (MND network).

**Catania, 17/10/2018 Dott. E. D’Amico**